Cocrystal Pharma Reports 2025 Financial Results, Advances Antiviral Drug Programs

Company's norovirus and coronavirus drug candidate CDI-988 progresses in clinical trials

Mar. 31, 2026 at 1:33pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the intricate molecular structure of a viral protease enzyme, conceptually illustrating Cocrystal's drug discovery platform focused on developing broad-spectrum antivirals.Cocrystal's innovative approach to targeting essential viral enzymes could unlock new treatments for hard-to-fight infections like norovirus and coronaviruses.Bothell Today

Cocrystal Pharma, a clinical-stage biotech company, has reported its 2025 financial results and provided updates on its antiviral drug development programs, including the ongoing Phase 1b norovirus challenge study for its lead candidate CDI-988 and progress on influenza and coronavirus programs.

Why it matters

Cocrystal's focus on developing broad-spectrum antivirals that target essential viral functions could lead to effective treatments for major public health threats like norovirus and coronaviruses, which currently lack approved therapies despite significant global health and economic impacts.

The details

Cocrystal's novel 3CL protease inhibitor CDI-988 is being evaluated as a potential treatment for norovirus and coronaviruses. The company has initiated a Phase 1b norovirus challenge study at Emory University, with the initial cohort assessing the infectivity of the GII.2 norovirus strain. Subsequent cohorts will receive CDI-988 or placebo. Cocrystal is also advancing its influenza programs, including the PB2 inhibitor CC-42344, which has shown activity against pandemic and seasonal influenza A strains, as well as resistant strains. Additionally, the company is pursuing the development of CC-42344 as an inhaled formulation and a broad-spectrum influenza A/B program.

  • In March 2026, Cocrystal enrolled the first subjects in its Phase 1b norovirus challenge study.
  • In August 2025, Cocrystal presented favorable Phase 1 safety and tolerability data for CDI-988, including a high-dose 1200 mg cohort, at the Military Health System Research Symposium.
  • In September 2025, Cocrystal received a Study May Proceed Letter from the FDA to conduct the Phase 1b norovirus challenge study.
  • In November 2025, Cocrystal completed an initial Phase 2a study for its influenza A candidate CC-42344, showing a favorable safety and tolerability profile.

The players

Cocrystal Pharma, Inc.

A clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2) and hepatitis C viruses.

Sam Lee, Ph.D.

President and co-CEO of Cocrystal Pharma.

James Martin

CFO and co-CEO of Cocrystal Pharma.

Emory University School of Medicine

The institution conducting Cocrystal's Phase 1b norovirus challenge study.

UK Medicines and Healthcare Products Regulatory Agency

The agency that authorized Cocrystal's Phase 2a human challenge study for its influenza A candidate CC-42344.

Got photos? Submit your photos here. ›

What they’re saying

“We are delighted to report that our norovirus human challenge study evaluating efficacy and safety of CDI‑988 is underway at Emory University School of Medicine. In our first cohort, healthy subjects are being inoculated with the GII.2 (Snow Mountain Virus) strain under highly controlled conditions.”

— Sam Lee, President and co‑CEO of Cocrystal

“Norovirus outbreaks can strike at any time of year in semi-closed environments such as cruise ships, military settings, and healthcare and assisted-living facilities. This constant threat underscores the need for an effective oral treatment and preventive that can be deployed whenever and wherever norovirus infections emerge.”

— James Martin, CFO and co-CEO of Cocrystal

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Cocrystal's focus on developing broad-spectrum antivirals that target essential viral functions could lead to effective treatments for major public health threats like norovirus and coronaviruses, which currently lack approved therapies despite significant global health and economic impacts.